U.S. poised to approve breakthrough treatment
The U.S. Food and Drug Administration is expected to approve exa-cel gene-editing treatment for sickle cell disease. Exa-cel would be the first approved medicine in the U.S. to use CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the treatment, which could cost around $2 million per patient. At age 19, Joe Tsogbe underwent his … Read more